Evidence map›Paper›PMID 39606608›Full record

ArticlePostepy dermatologii i alergologii2024

Comparison of 15% 5-aminolevulinic acid and 10% 5-aminolevulinic acid photodynamic therapy for the treatment of acne vulgaris: a split-face randomized pilot study.

Natalia Brzezińska, Barbara Bulińska, Natalia Zawadzka, Gustaw Roter, Aneta Szczerkowska-Dobosz

Abstract read
In one paragraph

Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Natalia BrzezińskaDepartment of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Barbara BulińskaDepartment of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Natalia ZawadzkaDepartment of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Gustaw RoterDepartment of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Aneta Szczerkowska-DoboszDepartment of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acne vulgaris is a highly prevalent skin disorder, driving the ongoing search for innovative treatment modalities. While numerous studies have demonstrated the effectiveness of photodynamic therapy (PDT) in managing acne vulgaris, there remains a lack of clear guidlines regarding optimal treatment parameters. Aim: To assess the efficacy and safety of 10% concentration 5-aminolevulinic acid-(ALA) in comparison to 15% ALA PDT for treating facial acne vulgaris. Material and methods: A randomized, double-blind, split-face clinical trial was conducted on 25 patients with moderate to severe acne ( Results: Both 15% and 10% ALA-PDT treatments demonstrated significant reductions in inflammatory acne lesion counts compared to the placebo: 10% ALA-PDT showed a reduction of 27.36% versus 12.64% for the placebo ( Conclusions: ALA-PDT is effective in treating acne vulgaris. However, ALA-PDT provides an advantage over red light only for inflammatory acne lesions. The study indicates that higher concentrations of ALA do not result in more significant reductions in acne lesions.

Indexed as

5-aminolevulinic acidacne vulgarislight therapyphotodynamic therapyred light

Identifiers

PMID39606608
PMCPMC11589636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.